HCELL-Modified MSC Compositions for Inflammation Site Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mesenchymal stem cells (MSCs) lack the ability to efficiently migrate to inflammatory sites due to the absence of E-selectin ligands, limiting their therapeutic efficacy in treating inflammatory disorders, and current pharmacologic treatments have adverse effects.
Innovation Solution
Modify MSCs ex vivo to express HCELL, a potent E-selectin ligand, enabling targeted delivery to inflammatory sites and enhancing their immunomodulatory and anti-inflammatory properties by increasing the production of molecules like IL-10.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are administered systemically to treat inflammatory disorders, then they can potentially reach inflammatory sites, but they fail to efficiently migrate to inflammatory sites due to lack of E-selectin ligands
Solution Approach 1:
The patent modifies the surface properties of MSCs by inducing expression of E-selectin ligands (such as sialyl Lewis X) through genetic engineering or biochemical treatment. This parameter change in cell surface glycosylation enables the cells to interact with E-selectin on endothelial cells, thereby facilitating their migration to inflammatory sites and resolving the contradiction between systemic administration and efficient target site delivery.
Solution Approach 2:
The patent introduces E-selectin ligands as intermediary molecules on the MSC surface that mediate the interaction between MSCs and the inflammatory site endothelium. These ligands act as molecular mediators that enable the cells to navigate the bloodstream and extravasate at inflammatory locations, solving the migration inefficiency problem.
2Reliability
If MSCs are modified ex vivo to express HCELL, then targeted delivery to inflammatory sites is enabled, but the complexity of cell preparation increases
Solution Approach 1:
The patent performs the HCELL modification on MSCs ex vivo before administration, which is a preliminary action that prepares the cells in advance for targeted delivery. This approach allows the complex modification process to be completed beforehand, ensuring that the cells are pre-equipped with the necessary targeting capabilities when introduced into the patient, thus managing complexity while maintaining delivery efficiency.
3Object-affected harmful factors
If current pharmacologic treatments are used to treat inflammatory disorders, then inflammation can be suppressed, but adverse effects occur
Solution Approach 1:
The patent converts the previously harmful or ineffective aspect of MSC therapy (inability to reach inflammatory sites) into a benefit by engineering E-selectin ligand expression. This transformation enables the cells to successfully deliver their therapeutic payload to the target sites, turning a limitation into an advantage and providing a safer alternative to pharmacologic treatments.
Data Source
AI summary
The present disclosure provides, inter alia, compositions, cell populations and pharmaceutical compositions and methods useful for the treatment of inflammatory diseases or disorders. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44+ cells modified ex vivo via treatment with a CD44 ligand for a period of time sufficient to prime the cells to produce elevated levels of one or more anti-inflammatory or immunomodulatory molecules relative to a native populations of CD44+ cells. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44+ cells modified ex vivo via a treatment that is effective to target cells to sites of inflammation.